VHH in
Cell Therapies
Small, stable and robust, VHH offer an attractive construct for incorporation as targeting agents in cell therapies.
VHH can also be easily multimerised to meet a variety of therapeutic needs, enabling refined cell targeting and modes of action while also minimising off-target toxicity. Away from the ectodomain, their small size also permits packaging of more sophisticated intracellular signalling domains, supporting the next generation of cell therapies.
Advantages of
VHH in Cell Therapy
Smaller constructs mean more space for multi-specific targeting modules or next-generation signalling domains.
References:
1. Jayaraman J et al. (2020) Ebiomedicine 58: 102931
2. Lamers CH, et al. (2011) Blood 117(1):72-82
3. Ackaert C et al. (2021) Front. Immunol. 12: 632687
4. Desmyter A et al. (1996) Nat Struct Biol 3(9): 803-811
Isogenica’s
VHH in CAR-T Resources
Review: The Application of Nanobody in CAR-T Therapy
Bao et al review the intersection between CAR-T development and VHHs against over a dozen tumour-associated antigens, with a focus on the bi-specific VHH therapy LCAR-B38M, now approved as CARVYKTI™.
VHHs enable multi-specific targeting for Tandem-CAR therapies
In this poster from 7th CAR-TCR Summit in Boston, we discuss the power of VHHs in creating multi-specific ectodomains.
Advantages of using VHH antibodies for CAR engineering
We explain the advantages of VHHs for CAR ectodomain targeting relative to traditional scFvs including size, solubility, and VHHs unique “magic finger” CDR3 domain.
Partnerships at Isogenica
Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.
